©
CDC/ James Gathany
Researchers at the Shoklo Malaria Research Unit (SMRU), part of MORU Tropical Health Network, have raised alarms over a widely used malaria rapid diagnostic test (RDT) that appears to deliver false-negative results. Published in the Malaria Journal, the study found that the Abbott-Bioline RDT delivered an alarming rate of false-negative results, potentially delaying treatment and undermining malaria control efforts. Researchers found that the test correctly identified only 18% of Plasmodium falciparum and 44% of Plasmodium vivax infections, compared to much higher detection rates by alternative brands.
The World Health Organization (WHO) issued an internal memo in April 2025 noting concerns over faint or false-negative results, but has yet to recommend halting use of the tests.
“It’s very possible that the fact that malaria was not diagnosed properly [has] meant more transmission, more disease,” said Professor François Nosten, Director of SMRU.
The findings are especially concerning for remote regions where rapid diagnostic tests are often the only available diagnostic tool. While other studies from Africa have reported better performance of the same test, experts warn that undetected cases could lead to increased transmission, especially in regions aiming for malaria elimination.